skip to Main Content

Evaluation of Waning Protection Against Pertussis Following GSK DTaP Vaccines

California, including the Kaiser Permanente Northern California (KPNC) population area, experienced the largest pertussis outbreak in more than 50 years during 2010-2011.This study will assess the durability of protection against pertussis in children who received 5 doses of DTaP vaccines made by GlaxoSmithKline, a major producer of vaccines in the US and globally. The primary objective is to assess waning protection against pertussis following 5 doses of DTaP among children who received all GSK pertussis vaccines.

Investigator: Klein, Nicola

Funder: GlaxoSmithKline PLC

Explore all studies and publications

Back To Top